Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 512.19
CVM's Cash to Debt is ranked higher than
75% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CVM: 512.19 )
CVM' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: 512.19

Equity to Asset 0.34
CVM's Equity to Asset is ranked higher than
54% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CVM: 0.34 )
CVM' s 10-Year Equity to Asset Range
Min: -0.51   Max: 0.99
Current: 0.34

-0.51
0.99
F-Score: 3
Z-Score: -14.75
M-Score: -2.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -12417.50
CVM's Operating margin (%) is ranked lower than
51% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CVM: -12417.50 )
CVM' s 10-Year Operating margin (%) Range
Min: -190240   Max: -928.57
Current: -12417.5

-190240
-928.57
Net-margin (%) -5731.88
CVM's Net-margin (%) is ranked higher than
51% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CVM: -5731.88 )
CVM' s 10-Year Net-margin (%) Range
Min: -154060   Max: 6851.63
Current: -5731.88

-154060
6851.63
ROE (%) -136.88
CVM's ROE (%) is ranked higher than
53% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. CVM: -136.88 )
CVM' s 10-Year ROE (%) Range
Min: -785.5   Max: 37.63
Current: -136.88

-785.5
37.63
ROA (%) -84.61
CVM's ROA (%) is ranked higher than
54% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CVM: -84.61 )
CVM' s 10-Year ROA (%) Range
Min: -273.96   Max: 27.73
Current: -84.61

-273.96
27.73
ROC (Joel Greenblatt) (%) -4062.99
CVM's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. CVM: -4062.99 )
CVM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5814.13   Max: -86.84
Current: -4062.99

-5814.13
-86.84
» CVM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CVM Guru Trades in

CVM Guru Trades in

Q4 2013

CVM Guru Trades in Q4 2013

Jim Simons 61,700 sh (New)
» More
Q1 2014

CVM Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CVM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.90
CVM's P/B is ranked higher than
64% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. CVM: 8.90 )
CVM' s 10-Year P/B Range
Min: 1.43   Max: 74.5
Current: 8.9

1.43
74.5
P/S 154.20
CVM's P/S is ranked higher than
55% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. CVM: 154.20 )
CVM' s 10-Year P/S Range
Min: 0   Max: 332
Current: 154.2

0
332
EV-to-EBIT -2.75
CVM's EV-to-EBIT is ranked higher than
60% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CVM: -2.75 )
CVM' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2.75

Current Ratio 4.17
CVM's Current Ratio is ranked higher than
74% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CVM: 4.17 )
CVM' s 10-Year Current Ratio Range
Min: 0.17   Max: 160
Current: 4.17

0.17
160
Quick Ratio 3.74
CVM's Quick Ratio is ranked higher than
73% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. CVM: 3.74 )
CVM' s 10-Year Quick Ratio Range
Min: 0.04   Max: 160
Current: 3.74

0.04
160

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.60
CVM's Price/Tangible Book is ranked higher than
69% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. CVM: 9.60 )
CVM' s 10-Year Price/Tangible Book Range
Min: 1.87   Max: 52.5
Current: 9.6

1.87
52.5
Price/Median PS Value 0.20
CVM's Price/Median PS Value is ranked lower than
51% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CVM: 0.20 )
CVM' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 5.39
Current: 0.2

0.1
5.39
Forward Rate of Return (Yacktman) -51.20
CVM's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. CVM: -51.20 )
CVM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -50.4   Max: -15.8
Current: -51.2

-50.4
-15.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LSRN.Germany
CEL-SCI Corporation was incorporated on March 22, 1983, in the state of Colorado. The Company is engaged in the research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. The Company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
» More Articles for CVM

Headlines

Articles On GuruFocus.com
CELSCISci Corp Reports Operating Results (10-Q) Feb 09 2011 
CELSCISci Corp Reports Operating Results (10-Q) Aug 16 2010 
CELSCISci Corp Reports Operating Results (10-Q) May 17 2010 
CELSCISci Corp Reports Operating Results (10-Q) Feb 12 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Jan 29 2010 
CELSCISci Corp Reports Operating Results (10-K) Jan 13 2010 
CELSCISci Corp Reports Operating Results (10-Q) Aug 14 2009 
CELSCISci Corp Reports Operating Results (10-Q) Aug 14 2009 

More From Other Websites
NEW STORY France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase... Jul 30 2014
8:31 am CEL-SCI Corp: France becomes 17th country to clear CEL-SCI for patient enrollment in its... Jul 30 2014
France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and... Jul 30 2014
CEL SCI CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 23 2014
CEL-SCI Has Been Cleared to Begin Patient Enrollment Jul 23 2014
NEW STORY CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into... Jul 22 2014
CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey Jul 22 2014
NEW STORY CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka Jul 21 2014
CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka Jul 17 2014
CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka Jul 17 2014
NEW STORY CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment Jul 15 2014
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment Jul 15 2014
NEW STORY CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development:... Jul 11 2014
CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things... Jul 11 2014
NEW STORY CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI'S Phase III Head and Neck Cancer... Jul 08 2014
CEL-SCI Receives Regulatory Clearance to Expand CEL-SCI’S Phase III Head and Neck Cancer Trial... Jul 08 2014
NEW STORY CEL-SCI Reports 93% Increase in Sequential Quarterly Patient Enrollment in Its Phase III... Jul 02 2014
CEL-SCI Reports Continued Increase in Sequential Quarterly Patient Enrollment in Its Phase III Head... Jun 03 2014
CEL-SCI receives approval to expand Phase III trial to U.K. Jun 02 2014
CEL-SCI Receives Approval to Expand Its Immunotherapy Phase III Head and Neck Cancer Trial into the... Jun 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide